G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

No significant difference seen in odds of postoperative pneumonia between adult GLP-1 receptor agonist users and nonusers.

GLP-1 receptor agonists are not associated with an increased risk for suicidality compared with DPP-4 inhibitors or SGLT-2 inhibitors.